SCHEMBL3843460

SCHEMBL3843460

CCOC(=O)c1c(-c2ccc(F)cc2)nc(N)nc1C(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCZ Q05513 1/20 0.52
MAPT P10636 3/20 0.51
KDM4E B2RXH2 3/20 0.51
ALDH1A1 P00352 3/20 0.51
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
HPGD P15428 2/20 0.51
PKM P14618 1/20 0.51
MAPK1 P28482 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
GRM6 O15303 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
GCGR P47871 1/20 0.46
PTGS2 P35354 1/20 0.45
TRPM8 Q7Z2W7 1/20 0.44
ADORA3 P0DMS8 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
GPR55 Q9Y2T6 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15481445 0.88 ALDH1A1 (0.47) PRKCZMAPTKDM4EALDH1A1NPC1
SCHEMBL1752471 0.86 GCGR (0.57) MAPTKDM4EALDH1A1NPC1RAB9A
SCHEMBL4787798 0.86 GCGR (0.43) PRKCZMAPTKDM4EALDH1A1NPC1
SCHEMBL3206 0.85 GCGR (0.47) PRKCZMAPTKDM4EALDH1A1NPC1
SCHEMBL2211 0.84 ALDH1A1 (0.47) PRKCZMAPTKDM4EALDH1A1NPC1
SCHEMBL3589 0.84 ALDH1A1 (0.44) PRKCZMAPTKDM4EALDH1A1NPC1
SCHEMBL8199366 0.84 ALDH1A1 (0.44) PRKCZMAPTKDM4EALDH1A1NPC1
SCHEMBL9562753 0.83 ADORA3 (0.52) MAPTKDM4EALDH1A1NPC1RAB9A
SCHEMBL2768 0.83 PTGS2 (0.53) PRKCZMAPTKDM4EALDH1A1NPC1
SCHEMBL6082682 0.82 ADORA2A (0.44) GCGRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273878-B2 Process for the preparation of pyrimidine compounds ASTRAZENECA UK LIMITED (GB) 2012-09-25 US disclosed
EP-1578731-B1 PROCESS FOR THE PREPARATION OF PYRIMIDINE COMPOUNDS ASTRAZENECA UK LTD (GB) 2009-11-11 EP disclosed
US-20090264654-A1 PROCESS FOR THE PREPARATION OF PYRIMIDINE COMPOUNDS ASTRAZENECA UK LIMITED (GB) 2009-10-22 US disclosed
EP-2088142-A2 Compounds and Processes AstraZeneca UK Limited (GB) 2009-08-12 EP disclosed
US-7524955-B2 Process for the preparation of pyrimidine compounds ASTRAZENECA UK LIMITED (GB) 2009-04-28 US disclosed
US-20060052604-A1 Process for the Preparation of Pyrimidine Compounds ASTRAZENECA UK LIMITED (GB) 2006-03-09 US disclosed
EP-1578731-A2 PROCESS FOR THE PREPARATION OF PYRIMIDINE COMPOUNDS AstraZeneca UK Limited (GB) 2005-09-28 EP disclosed
WO-2004054986-A2 PROCESS FOR THE PREPARATION OF PYRIMIDINE COMPOUNDS ASTRAZENECA UK LIMITED (GB) 2004-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264654-A1 PROCESS FOR THE PREPARATION OF PYRIMIDINE COMPOUNDS DPYD, RIOX2, CCNE1 PRKCZ 4365/4885MAPT 4839/4885KDM4E 640/4885
US-20060052604-A1 Process for the Preparation of Pyrimidine Compounds DPYD, RIOX2, CCNE1 PRKCZ 4361/4885MAPT 4836/4885KDM4E 653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.